These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2960064)

  • 1. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
    Murphy GP; Greco J; Huben R
    Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the gonadotrophin-releasing hormone agonist 'Zoladex' upon pituitary and gonadal function in hypogonadal (hpg) male mice: a comparison with normal male and testicular feminized (tfm) mice.
    Scott IS; Bennett MK; Porter-Goff AE; Harrison CJ; Cox BS; Grocock CA; O'Shaughnessy PJ; Clayton RN; Craven R; Furr BJ
    J Mol Endocrinol; 1992 Jun; 8(3):249-58. PubMed ID: 1385960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
    Mahler C; Verhelst J; Chaban M; Denis L
    Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist.
    Ward JA; Furr BJ; Valcaccia B; Curry B; Bardin CW; Gunsalus GL; Morris ID
    J Androl; 1989; 10(6):478-86. PubMed ID: 2533593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
    Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
    Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
    Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
    Namiki M; Nonomura N; Nakamura M; Okuyama A; Sonoda T; Nishimune Y; Matsumoto K
    Fertil Steril; 1987 Dec; 48(6):1012-7. PubMed ID: 2960563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
    Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C; Denis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.